吸入福莫特罗与沙丁胺醇治疗支气管哮喘的疗效和安全性比较

被引:3
作者
张静
陈小东
余霞珍
机构
[1] 复旦大学附属华山医院呼吸科
[2] 复旦大学附属华山医院呼吸科 上海
[3] 上海
关键词
福莫特罗; 长效β2受体激动剂; 支气管哮喘; 沙丁胺醇;
D O I
10.19577/j.cnki.issn10074406.2004.01.001
中图分类号
R562.25 [];
学科分类号
1002 ; 100201 ;
摘要
目的 :比较吸入福莫特罗与沙丁胺醇治疗成人慢性轻、中度支气管哮喘的疗效和安全性。方法 :将 80例患者采用随机、平行、对照的方法分为福莫特罗组 (n =4 0 ) ,吸入福莫特罗 4 5 μg ,bid ;沙丁胺醇组 (n =4 0 ) ,吸入沙丁胺醇 2 0 0 μg ,bid。疗程均为 12wk。观察 2组临床症状的改善情况和药物不良反应的发生率。结果 :福莫特罗明显改善患者的肺功能和临床症状 ,与沙丁胺醇比较 ,P <0 0 5 ;2组药物不良反应发生率比较 ,P >0 0 5。结论 :吸入福莫特罗控制哮喘临床症状优于沙丁胺醇
引用
收藏
页码:4 / 6
页数:3
相关论文
共 7 条
[1]  
Safety of formoterol turbuhaler at cummulative dose of 90 microg in patients with acute bronchial obstructive. Malolepszy J,Boszormeny G,Selroos O,et al. European Respiratory Journal . 2001
[2]  
FormoterolTurbuhaler4 5μg (delivereddose)hasarapidonsetand12hdurationofbronchodilation. SelroosO,EkstromT. Pulmphar macolTher . 2002
[3]  
Tolerabilityofinhaledhighdosesofformoterolandsalbutamolinasthmaticpatientsmaintainedontwicedaily12μg (9μgdelivered). LotvallJ,PssonG,LarssonP ,etal. European Respiratory Journal . 1997
[4]  
Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Rosenborg J,Bengtsson T,Larsson P,et al. European Journal of Clinical Pharmacology . 2002
[5]  
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Rosenborg J,Larsson R,Rott Z,et al. Respiratory Medicine . 2002
[6]  
Oxis(formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Seberova E,Audersson A. Respiratory Medicine . 2000
[7]  
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Woolcock A,Lundback B,Ringdal N,et al. American Journal of Respiratory and Critical Care Medicine . 1996